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ORIGINAL ARTICLE
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ABSTRACT
Background: Oral candidiasis (OC) has a profound effect on the life quality of immunocom-
promised patients, such as those undergoing chemotherapy. Objective: Systematic investi-
gation of clinical outcome and microbiological features of yeast isolates recovered from the
oral cavity of 150 Iranian patients with hematological malignancies. Design: MALDI-TOF MS,
21-plex PCR, and rDNA sequencing were used for identification. Antifungal susceptibility
testing (broth microdilution, CLSI M27-A3/S4) and genotypic diversity of yeast isolates
(amplified fragment length polymorphism) were assessed. Results: Nystatin treatment
resulted in 70% therapeutic failure and administration of 150 mg fluconazole (FLZ) + nystatin
for patients with OC relapse showed 70% clinical failure. Previous history of OC was sig-
nificantly correlated with FLZ treatment requirement and nystatin failure (P = 0.005, α <
0.05). Candida albicans (80.3%) and Kluyveromyces marxianus (C. kefyr) (12.7%) were the two
most prevalent yeast species isolated. FLZ and AMB exhibited the highest geometric mean
values. 21-PCR showed 98.9% agreement with MALDI-TOF MS. K. marxianus isolates had the
same genotype, while C. albicans isolates grouped in 15 genotypes. Conclusions: Marked rate
of therapeutic failure of nystatin necessitated OC treatment with systemic
antifungals. K. marxianus was the second most prevalent yeast and 21-plex PCR could be
considered as an inexpensive identification tool.
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In recent decades, we have witnessed an increase in the
number of patients prone to develop candidiasis [1,2].
According to epidemiological studies, more than
100 million people develop mucosal-surface fungal
infections annually [3] and among these candidiasis is
the most prevalent [4]. High-risk patients suffering
from oral candidiasis (OC) not only experience
a lower life quality [5], but importantly they may
develop life-threatening invasive candidiasis, where
the causative agents enter the bloodstream and cause
candidemia [6,7]. It is well-known that various immu-
nocompromised patient populations, such as those
infected with HIV [8,9] and inherited genetic disor-
ders[10], and cancer patients undergoing chemother-
apy are among the most susceptible individuals to
develop OC [5,7,11]. Indeed, meta-analysis studies
proved that chemotherapy and radiotherapy treatments
are independent risk factors for the development of
OC [5].
Previous studies indicated that C. albicans is still the
most common agent of OC, whereas non-albicans
Candida (NAC) species, although with a lower fre-
quency, are increasingly encountered in clinical settings
[12,13]. Unfortunately, the majority of these species
either intrinsically are less responsive to azole drugs
[14] or they acquire resistance to antifungal agents [15].
As a result, accurate identification at the species level is of
paramount importance to initiate a timely and appro-
priate therapeutic regimen. Nowadays, Sanger sequen-
cing and matrix-assisted laser-desorption time-of-flight
mass spectrometry (MALDI-TOF MS), owing to com-
prehensivity and accuracy, are being widely used in
clinical settings of developed countries (European coun-
tries) [16]. However, high costs required for the purchase
and maintenance of these devices hamper their use in
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developing countries [17,18]. In contrast, not only com-
mercial PCR devices cost significantly less ($2 K–$4 K),
but also the development of affordable and reproducible
PCR devices with initial costs of $130 contributed to the
popularity and extensive use of such a device in devel-
oping countries [19]. Therefore, PCR has been recom-
mended as a reliable identification platform by the
World Health Organization (WHO) [20]. Currently,
Arastehfar et al., developed a comprehensive multiplex
PCR that identifies the most prevalent yeast species caus-
ing infections in human [21].
Despite extensive studies on various immunocom-
promised populations [22–24], patients with hematolo-
gical disorders were less studied in Iran. Moreover,
none of the previous studies from Iran, extensively
and systematically investigated the clinical outcomes
that might lead to raising awareness of clinicians. As
a result, the purpose of this study was to investigate the
clinical outcome, distribution, antifungal susceptibility,
and genotypic diversity of yeast species isolated from
the oral cavity of patients suffering from hematological
disorders with oral candidiasis hospitalized in a referral
hospital (Firoozgar, Tehran, Iran). Moreover, due to the
lack of MALDI-TOF MS equipment in Iran, an alter-
native comprehensive multiplex PCR assay, 21-plex
PCR, was evaluated for its identification accuracy.
Material and methods
Study design
One-hundred and fifty patients suffering from hemato-
logical malignancies undergoing chemotherapeutic regi-
mens (1 December 2017 to 31 May 2018) retrospectively
were enrolled in this study. All patients were admitted in
the teaching hospital of Firoozgar, Tehran, Iran, which is
affiliated with the Iran University of Medical Sciences
(Tehran, Iran). Adults (18- year- old) without limitations
in sex and the hematologic malignancy types (acute lym-
phocytic leukemia, chronic lymphocytic leukemia, acute
myeloid leukemia, and chronic myeloid leukemia) were
recruited to this study.
Patients’ characteristics
All patients were examined by specialist clinicians for
signs and symptoms of OC. Patients that met the follow-
ing criteria were considered as OC positive, (a) presence
of thrush (pseudomembranous) in the oral cavity, and
(b) obtaining positive yeast growth from swab samples
[25]. Oral mucositis was defined by observing erythema-
tous and ulcerative lesions and all stages of mucositis
(mild, moderate and severe) were included [26]. This
study was reviewed by ethical committee members of
the Iran University of Medical Sciences (IUMS) and
ethical approval was granted (IR.IUMS.FMD.
REC.1397.098). Informed consent was obtained from
all patients whose identity was anonymized to
researchers through the use of a numerical code identi-
fier (1–150). Various demographic information, such as
age, gender, type of cancer, sampling season (to observe
the possible seasonality pattern) [27], clinical symptoms
of OC, and previous history of OCwere recorded for OC
positive patients.
Treatment options
In the neutropenic phase (absolute neutrophil count
<500 cells/mcl), patients were prophylactically treated
with Ciprofloxacin (500 mg BD/orally) and Acyclovir
(400 mg/TDS/orally) [28]. All patients initially under-
went treatment with topical nystatin and those with
relapse were treated with the combination therapy of
150 mg fluconazole (FLZ) and topical nystatin for
one week, which is not recommended by National
Comprehensive Cancer Network (NCCN) clinical
practice guideline [28]. Off note, owing to the
research nature of this study, authors did not have
any authority for the choice of antifungal agents used
to treat patients recruited to this study. The respective
decisions were made solely by in-charge clinicians.
Clinical specimens processing and culture
conditions
Symptomatic patients were examined and positive
OC cases were confirmed by specialist resident clin-
icians. Sterile cotton swab samples were taken from
the tongue and buccal mucosal lesions of patients and
immediately transferred into falcon tubes containing
sterile phosphate buffer saline (PBS 1×).
Initially, samples were subjected to direct micro-
scopic examination to observe the yeast structures, fol-
lowed by streaking on Sabouraud dextrose agar
medium (SDA, Sigma–Aldrich, USA) and incubated
at 35°C for 48 h. As some oral samples might harbor
more than a single species, and in order to obtain pure
colonies for each species, they were streaked on
CHROMagar (CHROMagar Candida, France) and
incubated for 48 h at 35°C. As results obtained from
the aforementioned conventional assays (direct micro-
scopy and CHROM agar) were not definitive, hence,
their respective phenotypic were not further analyzed
and the identity of each isolate was determined by LSU
rDNA sequencing, MALDI-TOFMS, and 21-plex PCR.
Identification of candida species and DNA
extraction
Yeast isolates were identified by Bruker MALDI-TOF
MS (MicroFlex-LT, Bremen, Germany) using
a previously described full extraction method [29].
Scores > 2 indicated successful identification to the spe-
cies level, and scores < 2 were regarded as correct identi-
fication at the genus level. Prior to proceeding with PCR
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identification, DNA samples were extracted by a CTAB
method [30]. Using yeast species obtained from this
study, the efficacy of a previously described 21-plex
PCR [21] was evaluated. Species with failed identification
in the first multiplex PCR were further tested by
the second multiplex PCR and in case of obtaining
negative results, isolates were checked by a third multi-
plex PCR [21]. PCR products were run on 2% agarose
gel, stained with GelRed (BioTium, USA) and visualized
with a gel documentation device (Gel Doc XR+, BioRad,
USA). Emerging Candida isolates were further checked
by sequencing of the D1/D2 domain of a large subunit of
the rDNA gene using LROR and LR5 primers [31].
Mixed samples identified as C. albicans and
C. dubliniensis by 21-plex were further tested using a
previously described hyphal-wall protein 1 primers [32].
Genotyping by AFLP
In order to assess the genotypic diversity of all isolates,
they were subjected to a previously published AFLP
protocol [33]. AFLP data were analyzed by
Bionumerics v7.6 (Applied Math Inc., Sint-Martens-
Latem, Belgium).
Antifungal susceptibility testing
The broth microdilution method of the Clinical and
Laboratory Standards Institute (CLSI, M27-A3/S4)
was used for antifungal susceptibility testing [34,35].
Eight routinely used antifungal drugs, including
amphotericin B (AMB) (Sigma Chemical Corporation,
St. Louis, MO), fluconazole (FLZ) (Pfizer, New York),
itraconazole (ITZ) (Santa Cruz Biotech, Dallas), vorico-
nazole (VOR) (Pfizer, New York), posaconazole (PSZ)
(MSD, Kenilworth, USA), 5-fluorocytosine (5-FC)
(Sigma Aldrich, Steinheim, Germany), caspofungin
(CAS) (Merck & Co., Inc.), and anidulafungin (AND)
(Pfizer, New York), were used. Plates were incubated at
35°C for 24 h and visual data were recorded. C. krusei
ATCC 6258 and C. parapsilosis ATCC 22019 were used
for quality control purposes. Depending on species,
clinical breakpoints and epidemiological cut-off values
were determined [35]. For isolates of C. albicans, the
MIC values of FLZ, ITZ, VRZ, CAS, and AND were
interpreted based on clinical breakpoints (CBP), while
PSZ, AMB and 5-FC MIC values were evaluated based
on epidemiological cut-off values (ECV) [35]. As for
C. tropicalis, the MIC values of FLZ, VRZ, AND, and
CAS were evaluated based on CBP and the rest of the
antifungals (PSZ, ITZ, AMB, and 5-FC) based on ECV
[35]. The MIC values of all antifungal agents obtained
for the isolates of K. marxianus and C. dubliniensis,
were evaluated based on ECV [35]. MIC50 for all anti-
fungals were defined as the minimum concentration of
drugs to inhibit 50% of fungal growth, whereas for
amphotericin B the MIC endpoint was considered as
the lowest concentration that inhibited 100% of fungal
growth compared to the drug-free control.
Statistical analyses
All the data presented in this study were analyzed by
SPSS software v.24 (Chicago, IL). Statistical analysis
included Pearson correlation Chi-square T-test, Eta
correlation coefficient (for nominal and continuous




The present study included 150 patients with hematolo-
gical disorders, among them 85 patients developed OC.
The majority of OC patients were men (n=53; 62.4%).
Women represented almost one-third of the patients
(n=32; 37.6%). The median age of the OC patients was
53 years. Acute myeloid leukemia (AML) with the pre-
valence of 53% constituted the most dominant hemato-
logical malignancy followed by chronic lymphocytic
leukemia (CLL) (n=17; 20%), acute lymphocytic leuke-
mia (ALL) (n=15; 18%), and chronic myeloid leukemia
(CML) (n=7; 8%). The vast majority of the patients
(n=51; 60%) were prescribed with chemotherapeutic
combination therapy of arsenic trioxide and cytarabine
and the rest of the patients with ritoximab/cyclophospha-
mide (n=15; 17.7%), cyclophosphamide (n=13; 15.3), and
fluorouracil (n=6; 7.1). Erythema, inflammation and
burning sensation of the buccal mucosa and tongue
were the most common complaints that were detected
in 59 patients (69.4%). C. albicans (n=69; 80.3%) was the
most prevalent causative agent of OC, followed by
K. marxianus (=Candida kefyr) (n=11; 12.7%),
C. tropicalis (n= 3; 3.5%), C. dubliniensis (n=2; 2.3%),
and Hanseniaspora opuntiae (n=1; 1.2%). One of the
patients concurrently was infected with both C. albicans
and H. opuntiae.
Lack of efficacy of nystatin for clearance of OC
Primarily all patients underwent treatment with topi-
cal nystatin, which resulted in OC clearance in
approximately 30% (n=28; 32.9%) of the cases.
Subsequently, the rest of the patients (n= 57; 67.1%)
were treated with a combination of 150mg of FLZ
and topical nystatin, among them 63% (n=36) experi-
enced at least one episode of OC relapse.
A significant correlation was noticed between the
previous experience of OC and treatment with FLZ
(α < 0.05, P = 0.005) and therapeutic failure with
nystatin (P < 0.05).
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Identification
MALDI-TOF MS consistent with LSU rDNA sequen-
cing successfully identified all isolates to the species
level (green score; >2), while the 21-plex PCR could
not identify the only isolate of H. opuntiae.
Interestingly, in agreement with primers targeting
hyphal wall protein-1 [32], two isolates showed double
bands representing both C. albicans and C. dubliniensis,
while both MALDI-TOF MS and sequencing identified
both as C. albicans (Figure 1). Those mixed samples on
CHROMagar yielded the same color as C. albicans
(green-colored colonies). As for the mixed sample con-
taining both isolates of C. albicans and H. opuntiae,
green and cream-colored colonies were observed on
CHROMagar, respectively.
AFLP genotyping
Although, infections due to C. albicans are mainly
endogenous, some studies have shown cases of hos-
pital-acquired infections for this species [36].
Accordingly, the high prevalence of C. albicans and
K. marxianus in the oral cavities of patients included
in this study, convinced us to perform the AFLP for
all isolates (except for H. opuntiae, n=1) to observe
the genotypic diversity. Moreover, all of the patients
enrolled in this study were from the same hospital
and the same unit (blood unit). One of the most
important findings of this study was a high number
of K. marxianus isolates (n=11; 12.7%) and through
AFLP those isolates belonged to the same genotype
(Supplementary Figure 1). As for the isolates of
C. albicans, we found three major clusters (C),
including C1 (n=16), C2 (n=17) and C3 (n=22) and
12 minor and unique genotypes each containing
a single isolate. No significant relationships were
found between genotype, the season of isolation,
and hospitalized ward. Two DNA samples of C. albi-
cans isolates did not yield any banding patterns
(probably due to the presence of inhibitors), therefore
they were excluded from the final AFLP figure.
Antifungal susceptibility testing
Antifungal susceptibility results and MIC values are
represented in Table 1. Among isolates of C. albicans,
only 2.8% (n=2) were resistant to FLZ (≥ 8 µg/ml)
and 4 isolates (5.7%) were intermediate for ITZ
(0.25–0.5 µg/ml), while they were all either suscepti-
ble to VRZ (≤ 0.12 µg/ml), CAS (≤ 0.25 µg/ml), and
AND (≤ 0.25 µg/ml) or wild-type (WT) for AMB (≤ 2
µg/ml), 5-FC (≤ 0.5 µg/ml), and PSZ (≤ 0.06 µg/ml).
All of the K. marxianus isolates showed WT pheno-
type for all antifungals used [5-FC (≤ 0.5 µg/ml),
AMB (≤ 2 µg/ml), FLZ (≤ 1 µg/ml), ITZ (≤ 0.12 µg/
Figure 1. Application of 21-plex PCR for identification of clinical isolates. The majority of the strains were identified in the first
multiplex PCR (C. albicans, C. dubliniensis, and C. tropicalis), the isolates of K. marxianus (C. kefyr) by the second multiplex PCR,
and the only isolate of Hanseniaspora opuntiae was not identified by any of the PCR reactions.
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ml), PSZ (≤ 0.25 µg/ml), VRZ (≤ 0.015 µg/ml), AND
(≤ 0.25 µg/ml), and CAS (≤ 0.0.3 µg/ml)]. All isolates
of C. tropicalis, except for two isolates that were
intermediate for ITZ (0.25–0.5 µg/ml), were suscep-
tible to FLZ (≤ 2 µg/ml), VRZ (≤ 0.12 µg/ml), AND
(≤ 0.25 µg/ml), and CAS (≤ 0.25 µg/ml) and WT for
PSZ (≤ 0.12 µg/ml), AMB (≤ 2 µg/ml), and 5-FC (≤
0.5 µg/ml). WT phenotype and low MIC values
against all antifungal agents were noticed for the
two C. dubliniensis isolates and the only isolate
of H. opuntiae, respectively. CAS, VRZ, and AND
showed the lowest geometric mean values for both
C. albicans and K. marxianus, while FLZ and AMB
showed the highest GM mean values for for isolates
of the two species, respectively.
Discussion
The worrisome escalation of cancer incidence may
facilitate the emergence of OC in this population
of patients. Unfortunately, despite a high annual
burden of OC and the possible link with the
development of candidemia [37] and even cancer
[10], many clinical and microbiological aspects of
this complication remain to be elucidated.
Conducting local, national, and worldwide studies
might result in a better clinical outcome, ease of
management of OC cases, establishing appropriate
empiric therapy, and finally lower hospital costs.
Consequently, in order to bridge the gap between
the lack of knowledge on clinical outcome and
Table 1. Antifungal susceptibility testing against yeast species isolated from oral lesions of patients with hematological
malignancies.
ECVa (µG/ml) CBPb (µG/ml)
Organism Antifungal <ECV >ECV S SDD I R GM Range
C. albicans (n=69) AMB 69 0 NA NA NA NA 0.439 0.12–1
FLZ 67 2 67 0 NA 2 0.461 0.125–8
ITZ 65 4 65 4 NA 0 0.046 0.016–0.5
VRZ 53 16 69 NA 0 0 0.022 ≤0.015–0.06
PSZ 69 0 NA NA NA NA 0.026 ≤0.015–0.06
CAS 69 0 100% NA 0 0 0.019 ≤0.008–0.12
AND 68 1 100% NA 0 0 0.026 0.015–0.12
5-FC 69 0 NA NA NA NA 0.060 <0.06–0.06
K. marxianus (n=11) AMB 10 0 NA NA NA NA 1.149 0.012–2C
FLZ 10 0 NA NA NA NA 0.326 0.12–0.5
ITZ 10 0 NA NA NA NA 0.053 0.06–0.25d
VRZ 9 1 NA NA NA NA 0.016 0.015–0.03
PSZ 10 0 NA NA NA NA 0.028 0.015–0.03
CAS 10 0 NA NA NA NA 0.014 ≤0.008–0.03
AND 10 0 NA NA NA NA 0.024 0.015–0.12
5-FC 10 0 NA NA NA NA 0.056 <0.06–0.12e
C. tropicalis (n=3) AMB 3 0 NA NA NA NA NA 0.12–0.5
FLZ 3 0 3 0 NA 0 NA 0.25–1
ITZ 3 0 NA NA NA NA NA 0.03–0.25
VRZ 1 2 1 NA 2 0 NA ≤0.008–0.25
PSZ 3 0 NA NA NA NA NA ≤0.015–0.06
CAS 3 0 3 NA 0 0 NA ≤0.008–0.06
AND 3 0 3 NA 0 0 NA 0.015–0.06
5-FC 3 0 NA NA NA NA NA ≤0.12–0.25
C. dubliniensis (n=2) AMB 2 0 NA NA NA NA NA 0.03–0.25
FLZ 2 0 NA NA NA NA NA 0.06–0.25
ITZ 2 0 NA NA NA NA NA 0.015–0.03
VRZ 2 0 NA NA NA NA NA <0.008–0.03
PSZ 2 0 NA NA NA NA NA 0.06–0.25
CAS 2 0 NA NA NA NA NA 0.008–0.06
AND 2 0 NA NA NA NA NA 0.015–0.06
5-FC 2 0 NA NA NA NA NA 0.06–0.12
H. opuntiae (n=1) AMB (0.5) NA NA NA NA NA NA NA 0.5
FLZ (1) NA NA NA NA NA NA NA 1
ITZ (0.03) NA NA NA NA NA NA NA 0.03
VRZ (0.015) NA NA NA NA NA NA NA 0.015
PSZ (0.015) NA NA NA NA NA NA NA 0.015
CAS (0.03) NA NA NA NA NA NA NA 0.03
AND (0.015) NA NA NA NA NA NA NA 0.015
5-FC (0.06) NA NA NA NA NA NA NA 0.06
a. Epidemiological cut-off value
b. Clinical breakpoint
c. For the isolates of K. marxianus, the epidemiological cut-off value of >2 were considered resistant to AMB
d and e. For the isolates of K. marxianus, the epidemiological cut-off value of ≥0.5 were considered resistant to ITZ and 5-FC
S; Susceptible, SDD; Susceptible dose-dependent, I; Intermediate, R; Resistant, NA; Not applicable
Geometric mean value was not calculated for species containing less than 10 isolates.
The only isolate of H. opuntiae showed low MIC values for all antifungal agents, which have are mentioned next to each antifungal used.
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microbiological features of OC among patients
suffering from hematological disorders we con-
ducted this study in Iran.
In our study, more than half (56%) of the enrolled
patients were positive for OC, from whom 86 yeast
isolates were recovered. Encountering such a high num-
ber of OC positive patients is likely due to the fact that
all our patients underwent chemotherapy [5], which is
known to be the main risk factor for the manifestation
of OC [5]. C. albicans (81%) was the most encountered
Candida species, followed by K. marxianus (12%),
C. tropicalis (3.5%), C. dubliniensis (2.3%) and
H. opuntiae (1.2%). It was not surprising that
C. albicans was the most prevalent Candida species, as
this fungus is the most abundant yeast agent inhabiting
mucosal surfaces of the gastrointestinal (GI), pulmon-
ary, and urinary tract [38,39]. Predominance of
C. albicans is in agreement with other studies [40–42],
while unlike those studies we found K. marxianus as
the second most frequently encountered yeast species.
Previous studies have shown that patients with hema-
tological disorders are prone to develop candidiasis due
to K. marxianus [27,43], which corroborates the high
rate of this yeast species in our study. Together with
Eddouzi et al., we reported the second clinical case of H.
opuntiae [44]. Studies of English abstracts published
from 2009 to 2018 revealed an increasing trend in the
spectrum and/or prevalence of emerging Candida and
yeast species isolated from the oral cavity of Iranian
HIV positive and cancer patients [22,45–48]. The
noted differences in the distribution of diverse yeast
species found in various studies might reflect the varia-
tions in patient subgroups, diet, sample types, or even
the administered antifungal regimen. In line with those
facts, application of informative and useful next-
generation sequencing platforms have revealed that
smoking [49], hygiene, and even the composition of
the tap water [50] may cause microbial diversity in the
oral microbiome.
Approximately 30% of our patients were success-
fully treated with nystatin and the remaining required
combination of 150 mg of FLZ + topical nystatin,
which indicates insufficient efficiency of this drug
for clearance of OC. Interestingly, we observed
a significant correlation between previous occurrence
of OC and the requirement of more than one period
of FLZ + nystatin treatment and nystatin therapeutic
failure. Some studies showed a superiority of nystatin
pastilles or pastille and suspension over nystatin
alone, whilst the adverse side effects on the gastro-
intestinal tract, unpleasant taste, use of high doses
and extended time of prescriptions are the drawbacks
of nystatin formulations [51]. On the contrary, other
studies have shown a similar efficacy of nystatin to
that of placebo and an inferiority to FLZ when used
in severe immunodeficient patients [52]. Although,
we did not test nystatin in our antifungal
susceptibility panel, other studies have shown high
MIC values for topical agents [48] and others recom-
mended the use of systemic antifungal drugs, such as
FLZ [5,53]. Moreover, randomized, double-blind
clinical trials have shown a higher efficacy of FLZ
and MCF when they were used in HIV-positive
patients suffering from OC [8,54]. In agreement
with other studies that showed a superiority of
a single dose of 750 mg of FLZ rather than two-
week-long 150 mg FLZ therapy in HIV-positive indi-
viduals [8], we found that almost 70% of patients
treated with 150 mg FLZ and topical nystatin therapy
showed OC relapse on more than one occasion.
Adopting such a single high dose of FLZ regimen
instead of a standard two-week long FLZ therapy of
150 mg, might result in lower risk of development of
FLZ-resistant isolates stemming from a more exten-
sive exposure time [55]. In case of FLZ-refractory
cases, utilization of other azole agents, including
PSZ, VRZ, ITZ [5], and micafungin [54] have been
recommended. This is in line with our findings that
ITZ, VRZ, and PSZ showed the lowest geometric
mean values and FLZ the highest. Nowadays, due to
the expanding spectrum of yeast species in clinical
settings that are possibly less responsive to azoles, it
might be useful to implement such a therapeutic regi-
men of systemic antifungals for patients suffering
from OC.
Approximately, 3% of the isolates of C. albicans
were resistant to FLZ and infected patients under-
went treatment with FLZ+nystatin, which is in con-
cordance with other studies that previous exposure
with FLZ results in the emergence of FLZ resistant
isolates in patients suffering from candidemia [56].
Although a newer generation of antifungals targeting
CYP51A have shown promising results when tested
in animal models infected with C. auris [57],
Cryptococcus neoformans [58], Cocciodiodes posadasii
and Coccidioides immitis [59], their efficacy remain to
be evaluated for the treatment of OC patients.
Moreover, if proved to be efficient when tested in
human OC positive cases, utilization of these drugs in
clinical settings might contribute in preserving the
limited systemic antifungal armamentarium and
reducing the burden of systemic drug-resistant yeast
species.
With regards to the identification of our clinical
yeast isolates, MALDI-TOF MS and 21-plex showed
100% and 99% consistency with LSU rDNA sequen-
cing, respectively. Although rare,MALDI-TOFMS suc-
cessfully identified H. opuntiae, while the 21-plex PCR
did not. Previous studies have shown the superiority of
MALDI-TOF MS for identification of clinically impor-
tant yeast species [60,61], but unfortunately, this device
is not available in Iran as a developing country.
However, PCR as an affordable and reproducible device
increasingly proves to be a popular identification
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platform in developing countries [19,20]. Moreover,
samples with mixed species could be differentiated via
21-plex PCR, while neither MALDI-TOF MS nor
Sanger sequencing were able to differentiate the respec-
tive yeast species.
Subjecting our isolates to AFLP revealed that all 11
isolates of K. marxianus were in the same cluster.
That may suggest that these isolates originated from
the same source. Unfortunately, as a limitation of our
study, we could not find the source of the
K. marxianus isolates. However, the lack of dairy
products in the hospital diet of our patients, pre-
cludes the fact that they have acquired K. marxianus
during their hospitalization stay. Moreover, it is even
likely that outside the hospitalization period those
patients might have consumed dairy products con-
taining K. marxianus and subsequently were infected
with this yeast.
Unexpectedly, we found 15 genotypes of C. albicans,
including three major clones constituting approxi-
mately 82% of C. albicans isolates and 12 minor geno-
types each represented by a single isolate. As the three
major genotypes encompassed more than 80% of the
C. albicans isolates, the phenomenon of intrahospital
transmission might be likely. Despite some studies
using AFLP have ruled out the intrahospital transmis-
sion phenomenon for C. albicans isolates recovered
from blood samples [62], others using pulse-field gel
electrophoresis (PFGE) proved otherwise [36].
Encountering with such a contradictory finding might
stem from the variation in the technology used, but it is
noteworthy that both AFLP and PFGE possess a high
discriminatory power. Unfortunately, similar to the
isolates of K. marxianus, we did not carry out any
screening protocols to prove the concept of intrahospi-
tal transmission for the C. albicans isolates, which is the
main limitation of our study. Although, AFLP proved
its superiority and higher resolution over multi-locus
sequence typing (MLST) [62], application of platforms
with a higher resolution, such as next-generation
sequencing, might provide a better explanation for the
intrahospital transmission phenomenon of C. albicans
isolates.
Conclusion
Clinical outcome data derived from our study was com-
pelling enough to persuade the clinicians to abandon the
usage of nystatin as a choice of antifungal therapy for the
treatment of OC positive patients with hematological
malignancies. Interestingly, K. marxianus after C. albi-
cans represented the second most prevalent yeast species
isolated from the oral cavity of our patients, and 21-plex
proved its efficiency for identification of clinically
encountered yeast species. Moreover, through perform-
ing AFLP, we found that the majority of C. albicans and
100% of K. marxianus isolates showed the same
genotypic background that might be an indication of
intrahospital transmission. However, proving this fact
requires environmental screening to find the same clin-
ical source, which is one of the shortages of our study.
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